Physicians' Academy for Cardiovascular Education
Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.
In a large population-based cohort study, BMI was associated with risk of hypertension, CHD, T2DM, elevated SBP and DBP based on causal mendelian randomization estimates, but not with stroke or pulse rate.
In diabetic patients at high cardiovascular risk, markers IL-6, hs-CRP, hs-cTnT and NT-proBNP were independent predictors of heart failure, while NT-proBNP also had an additive predictive value.
Based on the results of the LEADER trial, GLP-1 analogue liraglutide is approved by the FDA for CV risk reduction in type 2 diabetes
Systematic review of RCT evidence suggests that some TCM medications might improve CV risk factors and some may exert beneficial effects on ASCVD and chronic HF. Not all studies are of high methodological quality.
ADA 2017 Updated analysis provides evidence on the safety profile of dapagliflozin, including no imbalance in lower-limb amputations, and CVD-REAL analyses compare CV outcomes on SGLT2 inhibition with DPP4 inhibition.
ADA 2017 The investigational SGLT2 inhibitor ertugliflozin improved glycemic control in adults with type 2 diabetes. HbA1c reduced when combined with sitagliptin or metformin.
In the CANVAS trial program, diabetic patients with an increased CV risk treated with SGLT2 inhibitor canagliflozin had a significantly lower risk of CV events and a higher risk of amputation, compared with placebo.
ADA 2017 The DEVOTE trial compared injections of the long-acting insulin degludec with insulin glargine in high-risk T2DM adults and found degludec to be non-inferior for MACE.
ADA 2017 New LEADER analysis shows that liraglutide lowered risk of major CV events in T2DM patients at high CV risk, even if they had severe hypoglycemia. Hypoglycemia occurred less often with liraglutide.
ADA 2017 Results of two ODYSSEY studies with alirocumab were presented at the ADA Scientific Sessions, showing that alirocumab lowers LDL-c in patients with T2D, similar to those without T2DM.
During a satellite symposium at ESC Heart Failure 2017 in Paris, organised by PACE-CME, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.
In a large Diabetes Prevention Program, men with prediabetes treated with metformin for an average duration of 14 years had lower coronary calcium scores compared with the placebo group.
